AnaptysBio (NASDAQ:ANAB) Trading 6.5% Higher – Still a Buy?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price traded up 6.5% during mid-day trading on Monday . The stock traded as high as $35.70 and last traded at $35.37. 130,450 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 324,622 shares. The stock had previously closed at $33.22.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ANAB shares. JPMorgan Chase & Co. raised their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research note on Thursday, September 26th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a report on Wednesday, August 14th. Finally, Truist Financial raised their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.10.

AnaptysBio Stock Performance

The company has a market capitalization of $947.70 million, a price-to-earnings ratio of -5.42 and a beta of -0.29. The company has a 50 day moving average price of $35.29 and a 200 day moving average price of $29.10.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. Research analysts forecast that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of AnaptysBio stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the acquisition, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 23,940 shares of company stock worth $945,436. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio during the first quarter valued at about $38,000. Headlands Technologies LLC lifted its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 2,051 shares during the period. Duncan Williams Asset Management LLC acquired a new position in shares of AnaptysBio in the 3rd quarter valued at $282,000. Finally, Virtu Financial LLC acquired a new position in AnaptysBio in the 1st quarter valued at $222,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.